Recruiting

Geranylgeraniol

Sponsor:

Lindenwood University

Code:

NCT07502924

Conditions

Muscle Health

Muscle Strength

Body Composition

Eligibility Criteria

Sex: All

Age: 30 - 60

Healthy Volunteers: Accepted

Interventions

Dietary Supplement - Placebo

Geranylgeraniol (150 mg)

Geranylgeraniol (300 mg)

Study Details

Brief summary:

This study will evaluate the effects of daily geranylgeraniol (GG) supplementation on muscular strength, body composition, and aerobic capacity in healthy, physically active men and women. Approximately 60 participants aged 30-60 years will be enrolled in a randomized, double-blind, placebo-controlled, parallel-group trial lasting 8 weeks.

Participants will be assigned to receive either placebo, 150 mg GG, or 300 mg GG daily. Outcome measures will be assessed at baseline, week 4, and week 8 and include maximal strength (1RM bench press and leg press), fat-free mass, muscular endurance, aerobic capacity (VO2peak), and circulating biomarkers related to metabolism and health.

Conditions

Muscle Health

Muscle Strength

Body Composition

Study ID

NCT07502924

Start date

Mar 3, 2025

Status verified date

Mar, 2026

Completion date

Aug 1, 2026

Anticipated

Primary completion date

Aug 1, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 30 - 60

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Between 30 and 60 years old.
  • Body mass index values will range from >18.5 and <29.9 kg/m2
  • Subject agrees to maintain their existing dietary patterns throughout the study period.
  • Subject agrees to refrain from alcohol, caffeine, and strenuous exercise for 24 hours prior to each test day.
  • Is physically active, defined as at least 30 min of moderate exercise on at least 4 days a week.
  • Avoid consumption of pomegranate juice and avoid consumption of CoQ10, vitamin B3 and its precursors, L-carnitine, MK-4
  • Subject is willing and able to comply with the study protocol.
  • Subject has given voluntary, written, informed consent to participate in the study.

Exclusion Criteria:

  • BMI <18.5 or > 29.9 kg/m2
  • Positive medical history and/or is currently being treated for some form of heart disease, cardiovascular disease, kidney disease, renal failure, or has dialysis performed on regular intervals, Type I or Type II diabetes (determined as fasting blood glucose > 126 mg/dL), thyroid disease, liver disease or some form of clinically diagnosed hepatic impairment, immune disorder (i.e., HIV/AIDS), or neurological condition or disease.
  • Diagnosed with any affective disorder or other psychiatric disorder that required hospitalization in the prior year.
  • History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit).
  • Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea)
  • Genetic musculoskeletal and neurologic disorder known to affect skeletal muscle metabolism
  • Has donated blood in past 60 days
  • Diagnosed with or being treated for any endocrinological disorder and/or taking hormone boosting supplements (e.g. herbs) or hormone replacement therapy (prescribed/doctor ordered or not)
  • Had CoQ10 supplement in past 30 days. Had steroid medication one month before starting the study
  • Currently prescribed for the first time a statin drugs (i.e., Lipitor, Livalo, Crestor, Zocor, etc.) and/or a hypertension medication (i.e., Beta-blockers, ACE Inhibitors, Alpha blockers, - Vasodilators, etc.) within the past 6 months or has had their dosage or medication changed within the past 6 months
  • Current smoker (average of > 1 pack per week within the past 3 months) or has quit within the past six months. This includes all forms of nicotine
  • Intake of any drugs (prescribed or over the counter) or dietary supplements that are known or are purported to impact energy expenditure or weight loss (caffeine doses <300 mg/day is permissible)
  • Women with a history of hormone-related conditions such as endometriosis, fibroids, polycystic ovary syndrome
  • Women who are pregnant, planning to become pregnant, or lactating currently or within the past six months
  • Have a known sensitivity or allergy to any of the study products
  • History of alcohol or substance abuse in the 12 months prior to screening
  • Receipt or use of an investigational product in another research study within 30 days of beginning the study protocol
  • Has participated in other clinical trials focused on physical and muscle performance within the last year
  • They plan major changes in lifestyle (i.e., diet, dieting, exercise level, travel, etc.) during the study
  • Individuals who regularly compete as part of sanctioned athletic activities or those individuals who regularly train more than 360 minutes of exercise per week
  • Recent history (<3 months) of exercise training or weight loss (> 5%)
  • Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data

Study Design

Enrollment

70 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

placebo comparator: Placebo Comparator

Participants will ingest a placebo consisting of olive oil daily for 8 weeks. The supplement will be consumed with approximately 8 ounces of water at a consistent time each day.

active comparator: 150 mg Geranylgeraniol

Participants will ingest 150 mg of geranylgeraniol (GG) daily for 8 weeks. The supplement will be consumed with approximately 8 ounces of water at a consistent time each day.

active comparator: 300 mg Geranylgeraniol

Participants will ingest 300 mg of geranylgeraniol (GG) daily for 8 weeks. The supplement will be consumed with approximately 8 ounces of water at a consistent time each day.

Interventions

Dietary Supplement - Placebo

Participants will ingest a placebo consisting of olive oil daily for 8 weeks. The supplement will be consumed with approximately 8 ounces of water at a consistent time each day.

Geranylgeraniol (150 mg)

Participants will ingest 150 mg of geranylgeraniol (GG) daily for 8 weeks. The supplement will be consumed with approximately 8 ounces of water at a consistent time each day.

Geranylgeraniol (300 mg)

Participants will ingest 300 mg of geranylgeraniol (GG) daily for 8 weeks. The supplement will be consumed with approximately 8 ounces of water at a consistent time each day.

Primary outcome measure

  • Leg Press One-Repetition Maximum (1RM) [ Time Frame: Change from baseline (Week 0) to Week 8 ]
  • Bench Press One-Repetition Maximum (1RM) [ Time Frame: Change from baseline (Week 0) to Week 8 ]
  • Fat-Free Mass [ Time Frame: Change from baseline (Week 0) to Week 8 ]

Central Contacts and Locations

Central contacts

Anthony M Hagele, MS

6369494785ahagele@lindenwood.edu

Joesi M Morey, MS

6168266008jmorey@lindenwood.edu

Locations

Lindenwood University Exercise and Performance Nutrition Laboratory

Recruiting

Saint Charles, Missouri, United States, 63301

Contacts

Anthony M Hagele, MS

636-949-4785ahagele@lindenwood.edu

Joesi M Morey, MS

jmorey@lindenwood.edu

More Information

Sponsor

Lindenwood University

Last update posted

Mar 31, 2026

Last verified

Mar, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Lindenwood University on 2026-03-31.